Rubius Therapeutics (RUBY) is revealing for the first time Tuesday preclinical data to support efforts to transform red blood cells into new types of drugs that attack cancer.

Before today, Rubius was best known for going public with a $2 billion valuation despite zero drugs in clinical trials. There was also that creative re-imagination of its pipeline chart. The results unveiled Tuesday are still from experiments in test tubes and mice, but for Rubius CEO Pablo Cagnoni, they demonstrate that genetically augmenting red blood cells with molecules and proteins to stimulate the immune system is possible.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy